Core Viewpoint - The collaboration between Rakovina Therapeutics and NanoPalm Ltd. aims to develop novel small-molecule oncology therapeutics, starting with the dual PARP-HDAC inhibitor kt-3283, utilizing NanoPalm's advanced pLNP delivery technology [1][2][3]. Group 1: Collaboration Details - A non-binding Letter of Intent (LOI) has been signed to form a joint venture for co-developing oncology therapeutics [1]. - The joint venture will focus on advancing kt-3283 through late preclinical development and early clinical studies, while also evaluating additional AI-derived drug candidates [6][15]. - The collaboration combines Rakovina's AI-enabled drug discovery engine with NanoPalm's self-targeting pLNP delivery system, enhancing therapeutic delivery precision and efficacy [2][4]. Group 2: Technology and Innovation - kt-3283 is a potent small-molecule inhibitor that targets PARP and HDAC, showing enhanced cytotoxicity in preclinical studies, particularly in Ewing sarcoma, breast, and ovarian cancer models [3]. - NanoPalm's pLNP technology, originally developed for gene therapy, improves tissue specificity and systemic tolerability, representing a strategic entry into oncology [4][5]. - The collaboration aims to leverage AI-assisted design to enhance the delivery profile of small-molecule therapies, creating a robust pipeline for future commercialization [6][8]. Group 3: Operational and Strategic Aspects - The joint venture will be based in Saudi Arabia, aligning with the Kingdom's National Biotechnology Strategy and aiming for global development and commercialization [8][11]. - Intellectual property arising from the collaboration will be jointly owned, with each party retaining rights to their respective background IP [9]. - The partners will co-fund the joint venture and pursue third-party investments, sharing ownership, risk, and potential upside equally [15].

Core Viewpoint - Rakovina Therapeutics and NanoPalm Ltd. have signed a non-binding Letter of Intent to form a joint venture aimed at co-developing novel small-molecule oncology therapeutics, starting with the drug kt3283, utilizing NanoPalm's advanced pLNP delivery technology [1][6]. Company Overview - Rakovina Therapeutics is a biopharmaceutical company focused on cancer therapies, leveraging AI-powered drug discovery technologies, including the proprietary Deep Docking™ platform [13]. - NanoPalm Ltd. is a Saudi-based biotechnology company specializing in AI-designed pLNP delivery systems for gene and drug therapies, originally developed for gene therapy applications [11][12]. Joint Venture Details - The joint venture will focus on advancing kt3283, a dual-function PARP-HDAC inhibitor, through late preclinical development and early clinical studies, while also evaluating additional AI-derived drug candidates [6][9]. - The collaboration will be based in Saudi Arabia, with a global development and commercialization mandate, marking the first pLNP-oncology-focused biotech initiative in the region [9][16]. Technology and Innovation - Rakovina's AI-enabled drug discovery engine can rapidly screen billions of molecules against cancer targets, while NanoPalm's pLNP technology enhances therapeutic delivery precision and efficacy [2][4]. - kt3283 has shown strong preclinical activity in Ewing sarcoma, breast, and ovarian cancer models, demonstrating enhanced cytotoxicity compared to existing PARP and HDAC inhibitors [3][4]. Strategic Goals - The partnership aims to create a robust pipeline of novel therapeutics, with plans for global licensing and commercialization opportunities as the development pipeline matures [6][9]. - The joint venture will adhere to international regulatory standards, including those of the FDA, SFDA, and EMA, ensuring compliance and facilitating market entry [9][10].